Treatment of KrasG12D-driven, Lkb1−/− (Kras/Lkb1) mouse models of lung cancer with the combination of the SRC inhibitor dasatinib, MEK inhibitor AZD6244, and the dual PIK3CA and mTOR inhibitor BEZ235 resulted in decreased primary and metastatic lung tumours (Carretero et al, 2010). Here, STK11 is linked to lung carcinoma.